UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

NF-kappa B activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia

Tracey, L; Streck, CJ; Du, Z; Williams, RF; Pfeffer, LM; Nathwani, AC; Davidoff, AM; (2010) NF-kappa B activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia. LEUKEMIA , 24 (4) 806 - 812. 10.1038/leu.2010.2.

Full text not available from this repository.

Abstract

Acute lymphoblastic leukemia (ALL) harboring the t(4;11) translocation is associated with a very poor prognosis; innovative treatment strategies are required to improve the current 5-year survival rate of 30-40%. Interferon beta (IFN beta) has shown promise in the treatment of both solid and hematologic malignancies, although the short half-life and toxicity associated with high doses have limited its clinical utility. To overcome these limitations, we investigated the effect of continuous, gene transfer-mediated delivery of IFN beta using adeno-associated virus (AAV)-mediated expression, on ALL cells with the t(4; 11) translocation. We found that this method of IFN beta delivery resulted in complete remission of leukemia in a murine model. However, leukemic cells eventually became resistant to IFN beta and relapse was observed. Activation of NF-kappa B was identified as a mechanism for IFN beta resistance, and inhibition of NF-kappa B activity in resistant cells sensitized cells to IFN beta. IFN beta combined with agents that inhibit NF-kappa B could have therapeutic potential in the treatment of children with mixed lineage leukemia subtype ALL. Leukemia (2010) 24, 806-812; doi: 10.1038/leu.2010.2; published online 4 February 2010

Type: Article
Title: NF-kappa B activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia
DOI: 10.1038/leu.2010.2
Keywords: acute lymphoblastic leukemia, t(4;11) translocation, nuclear factor kappa B (NF-kappa B), interferon beta (IFN beta), INTERFERON-ALPHA RESISTANCE, T-CELL LYMPHOMA, CHROMOSOMAL REARRANGEMENT, ANTITUMOR-ACTIVITY, POOR-PROGNOSIS, LINE, INHIBITION, ANGIOGENESIS, DOXORUBICIN, CARCINOMA
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: http://discovery.ucl.ac.uk/id/eprint/1330932
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item